Filing Details
- Accession Number:
- 0001610520-24-000151
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-29 16:30:01
- Reporting Period:
- 2024-08-27
- Accepted Time:
- 2024-08-29 16:30:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1681682 | Endra Life Sciences Inc. | NDRA | National Commercial Banks (6021) | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610520 | Ag Group Ubs | Bahnhofstrasse 45 Zurich V8 CH-8001 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-08-27 | 3,715 | $0.55 | 146,012 | No | 4 | P | Indirect | By Subsidiary |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Subsidiary |
Footnotes
- This Statement is filed jointly by UBS Group AG for the benefit andon behalf of UBS Securities LLCand UBS Financial Services Inc., a wholly owned subsidiary of UBS Group
Billionaire Hedge Funds
